Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreKET ketamine maintenance treatment for treatment-resistant depression
2025-521330-29-00Phase 2Authorised
- Sponsor
- Ostfold Hospital Trust
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ketamine in major depressive disorder (MDD) and Bipolar II disorder (BP-II) (3 arms), sponsored by Ostfold Hospital Trust. Primary endpoints: Time-to-relapse after induction phase and Time-to-relapse after the last ketamine infusion. Planned start Oct 2026; status: authorised.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on 2025-521330-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521330-29-00.